قد يواجه أول مثبط لإنزيم KRAS، وهو دواء سوتوراسيبو، خطر السحب من السوق! – medfind.link
这是继武田的莫博替尼之后， 国庆假期期间又一项因为II期研究被加速批准适应症然后因为III期确证性研究失败而面临退市风险的药物！
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
الاسئلة الشائعة
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
